All In Biotech

Drug Trial Radar · NCT03940391

Effect of the Antihistamine Injection to Prevent Paradoxical Reaction During Sedative Endoscopy

Effect of an Adjunctive Sedative for the Patients With Histories of Paradoxical Reaction to Midazolam During Sedative Endoscopy

Last checked: Nov 20, 2026Latest source record: Apr 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

220

Planned (sponsor's estimate)

Start

May 1, 2019

Primary completion

Apr 14, 2020

Study completion Apr 14, 2020

Sponsor

Lead sponsor
Seoul National University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 7, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 69 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This single-blind prospective study is aimed to investigate the effect of antihistamine as an adjunctive sedative for the patients with histories of severe paradoxical reaction to midazolam during sedative endoscopy. Participating patients are to receive antihistamine intravenously in addition to midazolam. The primary outcome is the reduction of paradoxical reaction in the antihistamine combination group. The secondary outcome is to compare sedation quality, performance quality, reduction of total midazolam dose will be analyzed between antihistamine combination and midazolam only group.

Conditions

  • Endoscopy

Interventions

  • Chlorpheniramine and midazolamDrug

    Administration of chlorpheniramine injection as an adjunctive sedative during sedative endoscopy.

  • MidazolamDrug

    Administration of midazolam as a sedative during sedative endoscopy as routine clinical practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of severe paradoxical reaction (>= level 3)Time frame: 1 day

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Healthcare System Gangnam Center, Seoul National University Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.